Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors among patients with metastatic breast cancer: A systematic review and network meta-analysis

被引：0
|
作者：
Liu, Yi-Shao [1 ]
Dong, Kevin [1 ]
Park, Chanhyun [2 ]
机构：
[1] Univ Texas Austin, Austin, TX USA
[2] Univ Texas Austin, Coll Pharm, Hlth Outcomes Div, Austin, TX USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1218
引用
收藏
页码：575 / 576
页数：2
相关论文
共 50 条
  • [41] Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer
    Takahashi, Kaori
    Uozumi, Ryuji
    Mukohara, Toru
    Hayashida, Tetsu
    Iwabe, Midori
    Iihara, Hirotoshi
    Kusuhara-Mamishin, Kanako
    Kitagawa, Yuko
    Tsuchiya, Masami
    Kitahora, Mika
    Nagayama, Aiko
    Kosaka, Shinkichi
    Asano-Niwa, Yoshimi
    Seki, Tomoko
    Ohnuki, Koji
    Suzuki, Akio
    Ono, Fumiko
    Futamura, Manabu
    Kawazoe, Hitoshi
    Nakamura, Tomonori
    ONCOLOGIST, 2024, 29 (06): : e741 - e749
  • [42] Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor-positivemetastatic breast cancer: a systematic review and meta-analysis (vol 3, e2020312, 2020)
    Li, J.
    Huo, X.
    Zhao, F.
    JAMA NETWORK OPEN, 2020, 3 (11)
  • [43] Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies
    Niu, Ying
    Xu, Junnan
    Sun, Tao
    JOURNAL OF CANCER, 2019, 10 (22): : 5504 - 5517
  • [44] Efficacy and toxicity of endocrine therapy plus cyclin-dependent kinases 4/6 inhibitors (iCDK4/6) in metastatic breast cancer patients according to gBRCA status
    Bruno, L. I.
    Costanzo, M. V.
    Ostinelli, C. A.
    Nervo, A. A.
    Nadal, J.
    Colo, F.
    Loza, J.
    Loza, C. M.
    Ponce, C.
    Fabiano, V.
    Blanco, A. G.
    Perez de la Puente, C.
    Chacon, R. D.
    ANNALS OF ONCOLOGY, 2018, 29 : 98 - 98
  • [45] Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future
    Chen, Xiu
    Xu, Di
    Li, Xingjiang
    Zhang, Jian
    Xu, Weilin
    Hou, Junchen
    Zhang, Wei
    Tang, Jinhai
    JOURNAL OF CANCER, 2019, 10 (26): : 6608 - 6617
  • [46] Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?
    Genta, Sofia
    Mittica, Gloria
    Giannone, Gaia
    Ghisoni, Eleonora
    Valabrega, Giorgio
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S197 - S200
  • [47] Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
    Yildirim, Hasan Cagri
    Mutlu, Emel
    Chalabiyev, Elvin
    Ozen, Mirac
    Keskinkilic, Merve
    On, Sercan
    Celebi, Abdussamet
    Dursun, Bengu
    Acar, Omer
    Kahraman, Seda
    Aykan, Musa Baris
    Kaman, Omur
    Dogan, Akif
    Erdogan, Atike Pinar
    Celayir, Ozde Melisa
    Gunenc, Damla
    Guven, Deniz Can
    Bayoglu, Ibrahim Vedat
    Yavuzsen, Tugba
    Hacibekiroglu, Ilhan
    Inanc, Mevlude
    Kilickap, Saadettin
    Yalcin, Suayib
    Aksoy, Sercan
    BREAST, 2022, 66 : 85 - 88
  • [48] Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review
    Silvestri, Martina
    Cristaudo, Antonio
    Morrone, Aldo
    Messina, Claudia
    Bennardo, Luigi
    Nistico, Steven Paul
    Mariano, Maria
    Cameli, Norma
    DRUG SAFETY, 2021, 44 (07) : 725 - 732
  • [49] Are all cyclin-dependent kinases 4/6 inhibitors created equal?
    Antonio Marra
    Giuseppe Curigliano
    npj Breast Cancer, 5
  • [50] Are all cyclin-dependent kinases 4/6 inhibitors created equal?
    Marra, Antonio
    Curigliano, Giuseppe
    NPJ BREAST CANCER, 2019, 5 (1)
12345